Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (61-70 of 490) with videos related to

Pageof 49
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2024
S1-Guideline Sebaceous CarcinomaJochen Utikal, Pia Nagel, Verena Müller, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Skin toxicity of anti-cancer therapyJens Ulrich, Jörg T Hartmann, Wolfgang Dörr, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|February 1, 2019
[Merkel cell carcinoma]Christina Drusio, Jürgen C Becker, Dirk Schadendorf, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2004
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?Selma Ugurel, Monika Lindemann, Dirk Schadendorf, et al.
Current Opinion in Oncology|January 22, 2013
New developments in biomarkers for melanomaKlaus G Griewank, Selma Ugurel, Dirk Schadendorf, et al.
American Journal of Clinical Dermatology|April 22, 2024
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic UpdatesJürgen C Becker, Andreas Stang, David Schrama, et al.
Journal for Immunotherapy of Cancer|January 13, 2026
Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockadeJürgen C Becker, Georg Lodde, Maximilian Haist, et al.
Cancer Immunology, Immunotherapy : CII|April 7, 2017
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanomaViktor Umansky, Carolin Blattner, Christoffer Gebhardt, et al.
Journal of Cell Science|September 3, 2009
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cellsJochen Utikal, Nimet Maherali, Warakorn Kulalert, et al.
International Journal of Molecular Sciences|November 10, 2020
Cellular Reprogramming-A Model for Melanoma Cellular PlasticityKarol Granados, Juliane Poelchen, Daniel Novak, et al.
Pageof 49

Showing results (61-70 of 490) with videos related to

Sort By:
Pageof 49
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2024
S1-Guideline Sebaceous CarcinomaJochen Utikal, Pia Nagel, Verena Müller, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Skin toxicity of anti-cancer therapyJens Ulrich, Jörg T Hartmann, Wolfgang Dörr, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|February 1, 2019
[Merkel cell carcinoma]Christina Drusio, Jürgen C Becker, Dirk Schadendorf, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2004
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?Selma Ugurel, Monika Lindemann, Dirk Schadendorf, et al.
Current Opinion in Oncology|January 22, 2013
New developments in biomarkers for melanomaKlaus G Griewank, Selma Ugurel, Dirk Schadendorf, et al.
American Journal of Clinical Dermatology|April 22, 2024
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic UpdatesJürgen C Becker, Andreas Stang, David Schrama, et al.
Journal for Immunotherapy of Cancer|January 13, 2026
Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockadeJürgen C Becker, Georg Lodde, Maximilian Haist, et al.
Cancer Immunology, Immunotherapy : CII|April 7, 2017
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanomaViktor Umansky, Carolin Blattner, Christoffer Gebhardt, et al.
Journal of Cell Science|September 3, 2009
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cellsJochen Utikal, Nimet Maherali, Warakorn Kulalert, et al.
International Journal of Molecular Sciences|November 10, 2020
Cellular Reprogramming-A Model for Melanoma Cellular PlasticityKarol Granados, Juliane Poelchen, Daniel Novak, et al.
Pageof 49